International Stem Cell CORP
ISCO · OTCMCIK 1355790fmd_1HH5402NNXEBHRNSNQJM507SPJManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2006 to Jun 30, 2026, 69 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 7 | 7 | 11 | 9 | 7 | 7 | 8 | 8 | 9 | 9 |
| Cost of revenue | 2 | 2 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 |
| Gross profit | 5 | 5 | 7 | 6 | 4 | 4 | 5 | 5 | 5 | 5 |
| Research and development | 3 | 3 | 2 | 1 | 1 | 1 | 0 | 1 | 1 | 1 |
| Selling, general and administrative | 7 | 8 | 8 | 10 | 6 | 5 | 5 | 5 | 5 | 5 |
| Operating income | (5) | (5) | (3) | (6) | (3) | (2) | (0) | (1) | (0) | (0) |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest and investment income | – | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | 4 | (1) | 1 | 1 | 0 | 1 | (0) | 1 | (0) | (0) |
| Income before taxes | (1) | (6) | (2) | – | – | – | (0) | (0) | (0) | (0) |
| Income tax expense | 0 | 0 | 0 | – | – | – | – | – | 0 | 0 |
| Net income from continuing operations | (1) | (6) | (2) | – | – | – | – | – | (0) | (0) |
| Net income | (1) | (6) | (2) | (4) | (3) | (1) | (0) | (0) | (0) | (0) |
| Net income to common shareholders | (1) | (6) | (2) | (4) | – | – | – | – | – | – |